Related Experiment Videos
Lisinopril for severe congestive heart failure.
B F Uretsky1, J A Shaver, C S Liang
1University of Pittsburgh School of Medicine, Pennsylvania.
The American Journal of Cardiology
|February 21, 1989
Summary
Lisinopril, an angiotensin-converting enzyme inhibitor, demonstrated significant hemodynamic improvements in patients, including increased cardiac index and reduced pressures. Long-term use showed sustained effects and good tolerability with reversible renal effects in some.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Angiotensin-converting enzyme (ACE) inhibitors are crucial in cardiovascular disease management.
- Lisinopril is a potent ACE inhibitor with a long duration of action.
Purpose of the Study:
- To evaluate the hemodynamic effects of lisinopril in patients.
- To determine the dose-response relationship and long-term tolerability of lisinopril.
Main Methods:
- Hemodynamic assessment in 55 patients receiving 2.5, 5, and 10 mg of lisinopril.
- Follow-up of 47 patients for 3 months to assess functional capacity, symptoms, and renal function.
Main Results:
- Significant increases in cardiac index and reductions in pulmonary artery wedge, right atrial, pulmonary arterial, and systemic arterial pressures were observed.
- Dose-dependent effects were noted, with most parameters showing significant changes at 24 hours.
- Sustained hemodynamic effects, improved functional capacity, and acceptable tolerability were observed over 3 months, with reversible renal dysfunction in 26%.
Conclusions:
- Lisinopril exhibits long-lasting hemodynamic benefits.
- A dose-response relationship for lisinopril's hemodynamic effects can be established.
- Lisinopril demonstrates a favorable long-term safety and tolerability profile.